# Considerations for Including Tissue Biopsies in Clinical Trials - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-including-tissue-biopsies-in-clinical-trials/857b6b17-0402-45c3-8095-dcd482a60269 > FDA guidance document: Considerations for Including Tissue Biopsies in Clinical Trials. Issue date: January 07, 2025. Get complete insights and analysis. --- ## Details - Title: Considerations for Including Tissue Biopsies in Clinical Trials - Communication Type: Guidance Document - Product Type: biologics - Office Name: Office of the Commissioner - Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424 - Issue Date: 2025-01-07 - Comment Close Date: 2025-03-10 - Last Changed: 2025-06-04 - Docket Number: FDA-2024-D-2402 ## Related Documents - [Clinical Pharmacology Considerations for Peptide Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8) - [Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations](https://www.globalkeysolutions.net/guidances/guidance-document/bioavailability-and-bioequivalence-studies-submitted-in-ndas-or-inds-general-considerations/0cbdcef4-1b6b-45e5-8563-de1bb0a4e001) - [Research Involving Children as Subjects and Not Otherwise Approvable by an Institutional Review Board: Process for Referrals to Food and Drug Administration and Office for Human Research Protections: Draft Guidance for Institutional Review Boards, Investigators, and Sponsors](https://www.globalkeysolutions.net/guidances/guidance-document/research-involving-children-as-subjects-and-not-otherwise-approvable-by-an-institutional-review-board-process-for-referrals-to-food-and-drug-administration-and-office-for-human-research-protections-draft-guidance-for-institutional-review-boards-investigators-and-sponsors/26eaec4e-0434-4c59-a182-47818d614186)